DNSP-11
Also known as: DNSP-11
DNSP-11 is an 11-amino-acid peptide derived from the proGDNF (glial cell line-derived neurotrophic factor) precursor that is being studied for its neuroprotective and neurorestorative effects on dopaminergic neurons.
Last updated
Mechanism of Action
DNSP-11 is a dopamine neuron stimulating peptide cleaved from the pro-region of proGDNF, distinct from mature GDNF and acting independently of the canonical RET/GFRalpha-1 receptor complex. In preclinical models it promotes survival of dopaminergic neurons, increases dopamine synthesis and turnover, and reduces apoptosis through modulation of intracellular signaling and resistance to oxidative and excitotoxic stress. It has been shown to elevate striatal dopamine metabolites and improve behavioral measures in lesioned rodent models of Parkinson-like dopaminergic loss.
- Half-life
- Short; estimated minutes to a few hours (not well characterized in humans)
- Administration Routes
- subcutaneous, intranasal
- Research Status
- Preclinical
Reported Benefits
- Supports survival of dopaminergic neurons in preclinical models
- May increase dopamine synthesis and turnover
- Investigated for neurorestorative effects in Parkinson-like models
- Demonstrates neuroprotective activity against oxidative stress
- Reduces markers of neuronal apoptosis in animal studies
Potential Side Effects
- Human safety profile not established
- Possible injection-site irritation
- Unknown effects on central dopaminergic tone
- Potential immunogenicity with repeated exposure
Common Dosing
No validated human dosing exists; preclinical research has used microgram-range intracerebral or systemic administration in rodents. For research use only and not a guideline for human use.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Not for human therapeutic use
- Avoid in pregnancy or breastfeeding
- Unknown interactions with dopaminergic medications
Cerebrolysin
A peptide preparation derived from porcine brain tissue with neurotrophic and neuroprotective properties, used clinically in several countries for stroke, dementia, and traumatic brain injury.
P21 (P021)
P21 (P021) is a small peptidergic compound derived from the active region of ciliary neurotrophic factor, studied for promoting neurogenesis and synaptic plasticity. It is researched preclinically as a neuroprotective and cognition-enhancing agent.
Semax
A synthetic peptide derived from ACTH(4-10) developed in Russia and used there for cognitive enhancement, stroke recovery, and neuroprotection. Often used intranasally.
- View
Dopamine neuron stimulating actions of a GDNF propeptide
2010
- View
Dynamic changes in dopamine neuron function after DNSP-11 treatment: effects in vivo and increased ERK 1/2 phosphorylation in vitro
2014
- View
Methodology and effects of repeated intranasal delivery of DNSP-11 in a rat model of Parkinson's disease
2015
- View
Methodology and effects of repeated intranasal delivery of DNSP-11 in awake Rhesus macaques
2018
- View
Evaluation of the physical and in vitro protective activity of three synthetic peptides derived from the pro- and mature GDNF sequence.
2011